A New Protocol for Continuous Vancomycin Infusion Dosing.
Launched by KAROLINSKA UNIVERSITY HOSPITAL · Nov 22, 2021
Trial Information
Current as of June 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Start of continuous vancomycin infusion during the course of intensive care and at least one measurement of plasma concentration.
- Exclusion Criteria:
- • Vancomycin treatment within 96 h before admission to the unit.
- • Vancomycin treatment started with intermittent bolus infusions.
About Karolinska University Hospital
Karolinska University Hospital is a leading academic medical center in Sweden, renowned for its commitment to advanced healthcare research and innovative clinical practices. As a key sponsor of clinical trials, the hospital leverages its extensive expertise in medical research and collaboration with Karolinska Institutet, one of the world's foremost medical universities. The institution is dedicated to enhancing patient care through rigorous scientific investigation, focusing on a wide range of therapeutic areas. With a multidisciplinary approach and a strong emphasis on translational medicine, Karolinska University Hospital aims to bridge the gap between laboratory findings and clinical application, ultimately striving to improve health outcomes and advance medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials